FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

STATISTICS AND MEDICINE Previous Volume 354:1667-1669 April 20, 2006 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Bhatt, D. L. PubMed Citation

Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted^1,2,3,4 and can lead to further research that is misguided or, worse, to suboptimal patient care.

Consider a randomized, clinical trial designed to determine whether a new treatment is more effective than an established treatment and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal efficacy, as measured in terms of the primary end point. Then, subgroup analyses are conducted to assess whether different types of patients respond differently to the new treatment. . . . [Full Text of this Article]

Source Information

Dr. Lagakos is a professor of biostatistics at the Harvard School of Public Health, Boston, and a statistical consultant to the Journal.

Related Letters:

The Challenge of Subgroup Analyses
Eisner M. D., Lagakos S. W.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:211-212, Jul 13, 2006. Correspondence

This article has been cited by other articles:

• Hancock, M., Herbert, R. D., Maher, C. G. (2009). A Guide to Interpretation of Studies Investigating Subgroups of Responders to Physical Therapy Interventions. ptjournal 89: 698-704 [Abstract] [Full Text]  
• Rosenstein, R. S., Parra, D. (2009). Letter by Rosenstein and Parra Regarding Article, "Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel: Thrombolysis in Myocardial Infarction 38". Circulation 119: e601-e601 [Full Text]  
• McCabe, C., Bergmann, L., Bosanquet, N., Ellis, M., Enzmann, H., von Euler, M., Jonsson, B., Kallen, K.-J., Newling, D., Nussler, V., Paschen, B., de Wilde, R., Wilking, N., Teale, C., Zwierzina, H., Biotherapy Development Association, (2009). Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol 20: 403-412 [Abstract] [Full Text]  
• Cornelissen, J. J., van der Holt, B., Verhoef, G. E. G., van 't Veer, M. B., van Oers, M. H. J., Schouten, H. C., Ossenkoppele, G., Sonneveld, P., Maertens, J., van Marwijk Kooy, M., Schaafsma, M. R., Wijermans, P. W., Biesma, D. H., Wittebol, S., Voogt, P. J., Baars, J. W., Zachee, P., Verdonck, L. F., Lowenberg, B., Dekker, A. W., on behalf of the Dutch-Belgian HOVON Cooperative G, (2009). Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood 113: 1375-1382 [Abstract] [Full Text]  
• Chan, A.-W., Hrobjartsson, A., Jorgensen, K. J, Gotzsche, P. C, Altman, D. G (2008). Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 337: a2299-a2299 [Abstract] [Full Text]  
• Goldman, L., Gaspoz, J.-M. (2008). Cost-Effectiveness of Clopidogrel: Seeing through the Smoke. Med Decis Making 28: 803-809 [Abstract]  
• Kane, R. C. (2008). The Clinical Significance of Statistical Significance. The Oncologist 13: 1129-1133 [Abstract] [Full Text]  
• Douma, S., Petidis, K., Zamboulis, C., Messerli, F. H., Sulicka, J., Gryglewska, B., Cheah, C. Y., Wilson, M. D., Sutton, G., Beckett, N. S. (2008). Treatment of Hypertension in the Elderly. NEJM 359: 971-974 [Full Text]  
• Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J. I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. S., Srimuninnimit, V., Colleoni, M., Coates, A. S., Piccart-Gebhart, M. J., Goldhirsch, A., for the HERA Study Team, (2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19: 1090-1096 [Abstract] [Full Text]  
• American College of Cardiology/American Heart Asso, , Developed in Collaboration With the Canadian Cardi, , Endorsed by the American Academy of Family Physici, , 2007 Writing Group to Review New Evidence and Upda, , Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. JR (2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol 51: 210-247 [Full Text]  
• Antman, E. M., Hand, M., Armstrong, P. W., Bates, E. R., Green, L. A., Halasyamani, L. K., Hochman, J. S., Krumholz, H. M., Lamas, G. A., Mullany, C. J., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, 2004 Writing Committee Members, , Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., Lamas, G. A., Mullany, C. J., Ornato, J. P., Pearle, D. L., Sloan, M. A., Smith, S. C. Jr, Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Buller, C. E., Creager, M. A., Ettinger, S. M., Halperin, J. L., Hunt, S. A., Krumholz, H. M., Kushner, F. G., Lytle, B. W., Nishimura, R., Page, R. L., Riegel, B., Tarkington, L. G., Yancy, C. W. (2008). 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 117: 296-329 [Full Text]  
• Rossi, A., Gridelli, C., Bria, E. (2008). Thalidomide in Small-Cell Lung Cancer: Is It a Tombstone?. JCO 26: 160-160 [Full Text]  
• Pisters, K. M.W., Evans, W. K., Azzoli, C. G., Kris, M. G., Smith, C. A., Desch, C. E., Somerfield, M. R., Brouwers, M. C., Darling, G., Ellis, P. M., Gaspar, L. E., Pass, H. I., Spigel, D. R., Strawn, J. R., Ung, Y. C., Shepherd, F. A. (2007). Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline. JCO 25: 5506-5518 [Abstract] [Full Text]  
• Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., Drazen, J. M. (2007). Statistics in Medicine -- Reporting of Subgroup Analyses in Clinical Trials. NEJM 357: 2189-2194 [Full Text]  
• Manns, B., Klarenbach, S., Lee, H., Culleton, B., Shrive, F., Tonelli, M. (2007). Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878 [Abstract] [Full Text]  
• Thomas, Z., Fraser, G. L (2007). An Update on the Diagnosis of Adrenal Insufficiency and the Use of Corticotherapy in Critical Illness. The Annals of Pharmacotherapy 41: 1456-1465 [Abstract] [Full Text]  
• Gorelick, P. B. (2007). Combining Aspirin With Oral Anticoagulant Therapy: Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?. Stroke 38: 1652-1654 [Full Text]  
• Hochman, J. S., Steg, P. G. (2007). Does Preventive PCI Work?. NEJM 356: 1572-1574 [Full Text]  
• Mahaffey, K. W., Harrington, R. A. (2007). Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions. JAMA 297: 636-639 [Full Text]  
• Giacchetti, S., Gorlia, T., Garufi, C., Levi, F. (2007). In Reply. JCO 25: 606-607 [Full Text]  
• Bria, E., Di Maio, M., Cuppone, F., Nistico, C., Cognetti, F., Giannarelli, D. (2007). Should Subgroup Analysis of Randomized Clinical Trials Have a Direct Impact on Clinical Practice?. JCO 25: 605-606 [Full Text]  
• Glaser, R., Glick, H. A., Herrmann, H. C., Kimmel, S. E. (2007). Reply. J Am Coll Cardiol 49: 277-277 [Full Text]  
• Gorelick, P., Sechenova, O., Hennekens, C. H. (2006). Evolving Perspectives on Clopidogrel in the Treatment of Ischemic Stroke. J CARDIOVASC PHARMACOL THER 11: 245-248 [Abstract]  
• Mayne, S. T., Cartmel, B. (2006). Chemoprevention of Second Cancers. Cancer Epidemiol. Biomarkers Prev. 15: 2033-2037 [Abstract] [Full Text]  
• Appel, L. J. (2006). A Primer on the Design, Conduct, and Interpretation of Clinical Trials. CJASN 1: 1360-1367 [Abstract] [Full Text]  
• Winkelmayer, W. C., Zhang, Z., Shahinfar, S., Cooper, M. E., Avorn, J., Brenner, B. M. (2006). Efficacy and Safety of Angiotensin II Receptor Blockade in Elderly Patients With Diabetes. Diabetes Care 29: 2210-2217 [Abstract] [Full Text]  
• Ben-Yehuda, O. (2006). Physician Judgment in Cardiology: The Art of Medicine Lives On. J Am Coll Cardiol 48: 954-955 [Full Text]  
• Eisner, M. D., Lagakos, S. W. (2006). The challenge of subgroup analyses.. NEJM 355: 211-211 [Full Text]  
• Majure, D. T., Aberegg, S. K., Yusuf, S., Granger, C. B., Mehta, S. R. (2006). Fondaparinux versus enoxaparin in acute coronary syndromes.. NEJM 354: 2829-2829 [Full Text]  
• Walsh, B. T., Kaplan, A. S., Attia, E., Olmsted, M., Parides, M., Carter, J. C., Pike, K. M., Devlin, M. J., Woodside, B., Roberto, C. A., Rockert, W. (2006). Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial.. JAMA 295: 2605-2612 [Abstract] [Full Text]